Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
Status:
Recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after
treatment with combination or sequential ADT + Abi will be treated on a randomized, open
label study to determine if sequential treatment with high dose T and Enza will improve
primary and secondary objectives vs. continuous Enza as standard therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins